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ABSTRACT 
 
The anti-tumour properties of two fatty acid esters of maltotriose, 6’’-O-lauroylmaltotriose 
and 6’’-O-palmitoylmaltotriose, in which the 6-OH at the non-reducing end of the 
maltotriose has been regioselectively acylated, were studied. Both compounds were 
synthesised by transesterification of vinyl laurate or vinyl palmitate with maltotriose, in 
presence of immobilized lipase from Thermomyces lanuginosus. A mixture formed by 2-
methyl-2-butanol and dimethylsulfoxide (80:20 v/v) was the reaction medium. Their 
cytotoxic activities against two human cancer cell lines, Hep-G2 and HeLa, were studied. 
6’’-O-palmitoylmaltotriose showed 50% inhibition values (IC50) of 2.3 μM (1.7 μg/ml) for 
Hep-G2 and 3.6 μM (2.7 μg/ml) for HeLa cells, whereas 6’’-O-lauroylmaltotriose 
displayed a lower inhibitory effect. 6’’-O-palmitoylmaltotriose showed a marginal 
cytotoxicity to rat hepatocytes, confirming its potential as a new anti-tumour agent. 
 
Biotechnology and Applied Biochemistry (2005) 42, 35-39 
 3
INTRODUCTION 
 
Fatty acid sugar esters, especially those based on sucrose or glucose, are widely 
used in food and cosmetics as a consequence of their surfactant and antimicrobial 
properties [1]. Due to their low toxicity, non-antigenicity and biodegradability, 
carbohydrate esters have been investigated as potential anti-cancer agents. 
Maltose tetra- to hexa- fatty acid esters showed cytotoxicity against several tumor 
cell lines [2,3]. Maltose tetrapalmitate was also employed in syngenic Fischer rats as an 
immunoadjuvant against a weakly immunogenic transplantable mammary adenocarcinoma 
[4]. Nishikawa et al. studied the effect of fatty acid esters of sucrose [5] and maltose [6] 
towards Ehrlich ascites carcinoma in mice. The stearic, palmitic and myristic derivatives 
proved to be more effective than the shorter lauric and caprylic esters [6]. Nishikawa’s 
group also demonstrated that monoesters were more effective than the highly substituted 
analogs. In fact, water-solubility of sugar esters containing two or more long-acyl-chains is 
very low, which may detrimentally affect their biological activity. More recently, trehalose 
diesters of C8 to C12 fatty acids were found to inhibit tumor necrosis factor-α [7]. A 
similar effect was obtained with n-dodecyl-α-D-maltoside, a mimic of a disaccharide 
monoester [7]. Although different tumour-host systems have been employed, it can be 
concluded from the different investigations that (i) sucrose esters inhibit in less extension 
than maltose or trehalose esters, and (ii) fatty acid esters of monosaccharides do not 
display significant activity. 
All the above facts confirm that sugar esters are promising candidates as anti-
tumour agents. However, most of the derivatives assayed up to now are complex mixtures 
of regioisomers, and variations in the position of the acyl group may produce a great 
change in their molecular cytotoxic effect. Regioselective acylation of carbohydrates is an 
arduous task due to their multifunctionality [1,8]. The industrial synthesis of sugar esters is 
usually base-catalysed at high temperatures, has a poor selectivity, and gives rise to 
coloured side-products [9]. However, the enzyme-catalysed processes are notably more 
selective [10]. Lipases and proteases are the most useful enzymes for this purpose.  
Methodologies for enzymatic sucrose acylation need to find a medium where a 
polar reagent (the sugar) and a non-polar fatty acid donor are soluble and able to react in 
presence of the biocatalyst. We developed an enzymatic strategy for the synthesis of sugar 
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esters, which provides regioselective products [11]. The method was based on the use of a 
reaction medium formed by a tertiary alcohol (2-methyl-2-butanol) and a polar solvent 
(dimethylsulfoxide), which represents a compromise between enzyme stability and sugar 
solubility. We have successfully applied this strategy to the synthesis of esters of a 
monosaccharide (glucose) [12], several disaccharides (sucrose, maltose, leucrose, α-D-
dodecylmaltoside) [11,13,14], and even a trisaccharide (maltotriose) [13]. We have 
recently reported the antimicrobial effect of some of these derivatives against 
microorganisms involved in food spoilage [15] or in the development of dental caries [16]. 
In this work, the synthesis and anti-cancer properties of two maltotriose esters is 
described. 
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MATERIALS AND METHODS 
 
Lipase from Thermomyces lanuginosus (Lipolase 100L) was kindly donated by Novozymes 
A/S. Celite (diatomaceous earth, 0.13-0.20 mm, 80-120 mesh) was from BDH. 
Maltotriose, 2-methyl-2-butanol and 3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2H-
tetrazolium bromide (MTT) were from Sigma. Dimethylsulfoxide (DMSO) was supplied 
by Merck. Vinyl laurate was from Fluka. Vinyl palmitate was from TCI. All other 
reagents were of the highest available purity. Solvent and liquid reagents were dried over 3 
Å molecular sieves (Sigma), at least for 24 h before use.  
 
Enzymatic synthesis of maltotriose esters 
Synthesis of 6’’-O-lauroylmaltotriose and 6’’-O-palmitoylmaltotriose was carried out 
according to the methodology developed in our laboratory [13]. The lipase from 
Thermomyces lanuginosus was immobilised on Celite as described [11]. Maltotriose (0.6 
mmol) was dissolved in 2 ml of DMSO, and slowly added to 8 ml of 2M2B. The 
immobilized lipase (0.5 g) and molecular sieves (3 Å, 0.5 g) were then added and the 
suspension maintained 30 min at 40 ºC with magnetic stirring. Then, fatty acid vinyl ester 
(3 mmol) was incorporated. After 24 h at 40ºC, the mixture was cooled, filtered and 
washed with 3 volumes of 2M2B. The maltotriose monoesters were precipitated by 
addition of 2.5-10 volumes of n-heptane, the solid recrystallised in acetone, and dried in 
vacuo. The products were fully characterised by chromatography and spectroscopic 
techniques (HPLC, NMR, IR, HRMS). 
 
In vitro cytotoxicity assays. 
Cell survival was measured by means of the colorimetric MTT test [17]. Dose response 
curves for each cell line were measured at six different concentrations. All the cytotoxicity 
and cell viability assays were performed in triplicate. The duration of cell treatment was 
chosen on the basis of data available in the literature and our data from preliminary 
experiments. Results are expressed as a percentage of cell growth inhibition compared with 
a control in absence of ester. 
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RESULTS AND DISCUSSION 
 
In contrast with the corresponding mono- and disaccharide derivatives, the anti-
tumour activity of fatty acid esters of trisaccharides such as maltotriose has not been 
reported before. As part of our investigation on novel applications of sugar esters, the in 
vitro cytotoxic activity of the enzymatically-synthesised 6’’-O-lauroylmaltotriose and 6’’-
O-palmitoylmaltotriose against two human hepatocarcinoma cancer cell lines, Hep-G2 and 
HeLa, was evaluated. These cell lines were selected as a model system because they are 
commonly employed in studies of anti-tumour effects of potentially active chemicals.  
Analytical-grade 6’’-O-lauroylmaltotriose and 6’’-O-palmitoylmaltotriose (purity 
>99%) were regioselectively obtained using the lipase from Thermomyces lanuginosus as 
biocatalyst [13]. Fig. 1 represents the protocol followed to synthesize and purify both 
compounds. The synthesis was performed by transesterification of vinyl laurate or vinyl 
palmitate with the sugar in a mixture 2M2B:DMSO 80:20 (v/v). The carbohydrate was 
dissolved in 2 ml DMSO, and this was slowly added to 8 ml of a 2M2B. Maltotriose 
solubility in such medium is notably higher than in pure 2M2B, which favours reaction 
kinetics. In addition, the inactivation of the enzyme is greatly reduced compared with pure 
DMSO. The above process contrasts with the great difficulties encountered by other 
researchers to acylate this trisaccharide [18]. Sugar esterification is more difficult when 
increasing the polymerisation degree of the carbohydrate, because its hydrophilicity makes 
higher and its solubility in solvents of intermediate polarity such as 2M2B diminishes.  
The structure of the purified esters was determined by 1H-NMR and 13C-NMR. Fig. 
2 shows the 1H-NMR spectrum of 6’’-O-lauroylmaltotriose. As the O-acylated carbon and 
the corresponding H-6 protons were shifted downfield, we could unequivocally assign that 
the 6-OH of glucose at the non-reducing end was regioselectively acylated (Fig. 1). Deng 
et al. also succeeded in the acylation of maltotriose and maltotetraose [19]; they esterified 
the 6-OH of the second glucose unit from the reducing end, but using a coupled process 
involving a lipase and a cyclodextrin glucanotransferase.  
The novel maltotriose esters here synthesised are excellent non-ionic surfactants 
[20] and can be used to enhance the bioavailability of polychlorinated biphenyls (PCBs) for 
further biodegradation [21]. To determine whether these compounds could exert a potential 
pharmacological effect, studies on differential toxicity were undertaken. The study was 
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conducted with several cellular models. HepG2 is a cell line derived from a human 
hepatoma and is representative of a differentiated tumour cell. HepG2 shows a limited, but 
measurable, hepatic functionality [22-24]. HeLa, on the other hand, is a rather 
undifferentiated cell line with notable cell growth capability [23]. 
Cell survival was measured by means of the colorimetric MTT test [17]. Results are 
shown in Fig. 3, expressed as the percentage of cell growth inhibition compared with a 
control in absence of ester. A first insight into the experimental data shows that 6’’-O- 
palmitoylmaltotriose was more toxic to both cell lines than 6’’-O-lauroylmaltotriose. 6’’-O-
palmitoylmaltotriose treatment resulted in a dose-dependent decrease of cell viability of 
both Hep-G2 and HeLa cells (Fig. 3B), and it became noticeable that the hepatoma cell 
line showed a somewhat higher susceptibility than the less differentiated HeLa cell. In 
contrast, 6’’-O-lauroylmaltotriose showed no significant effect on Hep-G2 and a low 
inhibitory effect on HeLa (Fig. 3A). Curve analysis allowed graphic estimation of the 
concentration causing 50% cell growth inhibition (IC50). The IC50 values for 6’’-O-
palmitoylmaltotriose against the growth of Hep-G2 and HeLa cancer cell lines were 2.3 
µM and 3.6 µM, respectively. Both concentrations correspond to values below 3 µg/ml. 
These concentrations are lower than those reported for trehalose diesters (7.4-23 µM) [7], 
dodecyl-α-D-maltoside (23 µM) [7], and highly esterified analogues of maltose (10-100 
µM) [2-5].  
To investigate whether a real benefit of these compounds could be derived, the 
toxicity of both compounds on rat hepatocytes was evaluated (Fig. 4). It can be observed 
that differentiated hepatocytes were clearly less sensitive to palmitoyl maltotriose than 
transformed cell lines Hep-G2 and HeLa. Such differential toxicity of the palmitoyl ester 
towards cancer cells −at least 2 orders of magnitude higher than the observed towards 
differentiated hepatocytes− is a first positive criterion in favour of a potential use of this 
kind of compounds. 
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CONCLUSION 
 
To our knowledge this is the first report on the anti-tumour activity of an acylated 
derivative of a trisaccharide. On the basis of the results presented it can be concluded that 
novel 6’’-O-palmitoylmaltotriose is a promising anti-tumour agent with a strong ability to 
inhibit cancer cell proliferation. Although the IC50 values towards HeLa cells are not as 
low as those reported for other chemicals (e.g. 0.1 μM for several triterpenoids [25]), the 
values obtained in this work are lower than 4 µg/ml, a limit put forward by NCI for 
classification of compounds as potential anti-cancer drugs [26]. In addition, the low 
toxicity and notable hydrophilicity of carbohydrate esters offer practical advantages. 
Moreover, taking the aforementioned data, we consider that trisaccharide esters are more 
promising inhibitors than the corresponding mono- and disaccharide counterparts. The 
possibility of obtaining these compounds in high yield and purity by using our new 
enzymatic methodology makes pure maltotriose esters easily available. In addition, novel 
maltotriose esters have been isolated from plants, e.g. from the roots of Polygala arillata 
[27]. Further studies will be necessary to elucidate the inhibition mechanism of tumour 
cells proliferation by the new maltotriose fatty acid esters hereby described.  
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FIGURE LEGENDS 
 
FIG. 1. Reaction scheme for the synthesis of 6’’-O-acylmaltotrioses. 
 
FIG. 2. 1H-NMR spectrum of the synthesized 6’’-O-lauroylmaltotriose. The spectrum 
was recorded at 30 °C on a Varian INOVA (300 MHz) spectrometer dissolving the ester in 
CD3OD. 
 
FIG. 3. Cell viability of several cellular models after exposure to maltotriose esters. 
(A) 6’’-O-lauroylmaltotriose and (B) 6’’-O-palmitoylmaltotriose. Hep-G2 (?) and HeLa 
(?) cell lines were exposed to monoester 24 h, and cell viability was measured by the 
MTT test after a further 24 h treatment. Standard deviations, calculated from three 
independent experiments, were in all cases between 5 and 10%. The data were fitted to a 
four parameter logistic curve using the Sigma Plot 2001 software. 
 
FIG. 4. Toxicity of maltotriose esters towards rat hepatocyte cells. Cell lines were 
exposed to 6’’-O-lauroylmaltotriose (?) and 6’’-O-palmitoylmaltotriose (?) for 24 h, and 
cell viability was measured by the MTT test after a further 24 h treatment. Standard 
deviations, calculated from three independent experiments, were in all cases between 5 and 
10%.
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Fig. 2 
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